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Summary
Objective: Because outcome data inform and drive healthcare decisions and im-
provement of patient care, this study aimed to gain a deep understanding of sociode-
mographic profiles and treatment outcomes of newly presenting and recently 
diagnosed persons living with epilepsy (PwE) at a tertiary epilepsy center in Rwanda.
Methods: In June 2016 (T1), as a first stage of this single- center cohort study, an 
ambispective chart review was conducted on baseline sociodemographic and disease 
characteristics of PwE using a structured questionnaire. Missing data were obtained 
by phone interview. In 2017, follow- up data were collected by phone interview on 
treatment outcomes after 15- months (T2).
Results: Of 406 PwE screened, 235 were included at T1 and outcomes on 166 PwE 
were obtained at T2. More than 70% were <20 years of age, with a male preponder-
ance. A high number of patients were aged ≥20 years, were single (67.4%), unem-
ployed (41.5%), and had no formal education or primary level education (53.9%), 
possibly reflecting stigma. A mean delay in diagnosis since first seizure increased 
with age at first seizure, amounting to 3 years for patients aged ≥20 years. At T2, 
69.6% of 166 patients who could be contacted reported no seizures in the previous 
month. Valproate monotherapy was the most frequently prescribed treatment. At T2, 
47% had discontinued treatment, which was often not recommended by a physician, 
despite medical insurance coverage in >90% of patients. Only 19% reported an ad-
verse event. Marked and partial improvement in quality of life (QoL) was reported 
by, respectively, 50.9% and 32.7% of patients.
Significance: Encouraging results on improved seizure control and QoL were observed at 
follow- up. The treatment gap remains high due to loss to follow- up and treatment discon-
tinuation. In this article, we discuss needs and recommendations for improving patient care, 
requiring concerted efforts of stakeholders at all levels of the healthcare system.
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1 |  INTRODUCTION
In sub- Saharan Africa, epilepsy is associated with a particu-
larly high burden of disease.1,2 This is not only due to a greater 
prevalence of the disease, but also to a poor healthcare in-
frastructure with limited resources and limited access to an-
tiepileptic drugs (AEDs), and to cultural barriers leading to 
stigma.3,4 The greater prevalence of epilepsy in sub- Saharan 
populations compared to Latin American and Asian popula-
tions, is due mainly to the presence of a higher number of com-
bined risk factors such as cerebral malaria, neurocysticercosis, 
meningitis, human immunodeficiency virus (HIV) infection, 
toxocariasis, perinatal events, and traumatic brain injury.1,5,6
In Rwanda, the prevalence of active epilepsy was esti-
mated to be 4.9% in 2005, one of the highest in sub- Saharan 
Africa.7 Since then, there have been concerted efforts to in-
crease the recognition and understanding of the disease and 
to reduce the treatment gap through mobile teams educating 
about epilepsy diagnosis and treatment in rural areas, the 
creation of the Rwandan Organization Against Epilepsy, ca-
pacity building, and several nongovernmental organization 
(NGO) activities.8 One of the main hospitals that provides 
care for persons living with epilepsy (PwE) is the CARAES 
Neuro- Psychiatric Hospital in Ndera (NPH), on the outskirts 
of the capital city, Kigali, founded in 1968 by the Brothers of 
Charity. Over the years, NPH has evolved to provide special-
ized psychiatric and neurological services and also acts as the 
tertiary referral center for epilepsy for the entire country.
This study was conducted to gain insight into the socio-
demographic profiles of patients attending the NPH and the 
impact of care and treatment provided by the hospital on epi-
lepsy and the day- to- day lives of PwE.
2 |  METHODS
2.1 | Study setting
This single- center ambispective cohort study was conducted 
at the NPH between January 2016 and September 2017. The 
study was approved by the ethics board of the NPH and institu-
tional review board of the University Hospital Center—Kigali 
(CHU- K). Full details of the study, including objectives and 
methodology, were conveyed orally to all participants. Given 
the large number of participants with poor literacy, only ver-
bal consent was obtained from most of patients and recorded 
in their medical records. For patients ≤18 years of age, verbal 
consent was obtained from their parents/caregivers.
2.2 | Study participants
Medical charts of all patients attending the NPH neurol-
ogy department for the first time between January and June 
2016 were screened for a diagnosis of epilepsy. Epilepsy 
was defined as a history of 2 or more unprovoked seizures 
according to recommendations by the International League 
Against Epilepsy (ILAE).9,10 Only patients presenting for 
the first time to the clinic, with a first seizure or diagnosis 
since less than a year were included. All diagnoses were 
established or confirmed by a trained neurologist, psy-
chiatrist, or family physician with experience in epilepsy. 
Seizure classification was based on information from medi-
cal records and is using the ILAE 2011 classification.11
2.3 | Data collection
In the first stage of the study (T1), in June 2016, a retrospec-
tive chart review of the first visit was conducted. Baseline 
sociodemographic data and information on disease character-
istics, including age at epilepsy onset, seizure type(s), seizure 
frequency, diagnostic tests, and treatment history were ob-
tained from medical charts, using a predefined paper- based 
questionnaire. Patients were also contacted by telephone to 
obtain additional information.12,13
In the second stage of the study performed in 2017, 
15 months after first visit (T2), patients or caregivers were 
contacted again for follow- up using a predefined structured 
phone interview, performed by the nursing staff of the neu-
rology department. Nurses were trained in the fundamentals 
of epilepsy and in handling conversations using a paper- based 
questionnaire. Patients were asked about their treatment sta-
tus, seizure frequency over the last 30 days, adverse events 
(AEs), and quality of life (QoL).
Given the lack of validated instruments in the local lan-
guage Kinyarwanda, the impact of treatment on QoL could 
not be assessed directly. Therefore, we asked patients about 
disease- related comorbidities and whether they had noticed 
any difference in their day- to- day life since their first visit at 
the center, using a 4- item scale: marked improvement, some 
improvement, no change, and deterioration. For patients 
Key Points
• Low education (54%) and high unemployment 
(41%) were observed in PwE
• After 15 months of observation (follow-up), 
nearly 70% of patients reported at least 30days of 
seizure freedom
• More than 80% of patients reported marked and 
partially restored QoL
• Treatment gap and dropout rate are high
• Recommendations for future epilepsy care in 
Rwanda
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unable to respond adequately due to age or disease severity, 
parents/caregivers were asked to respond.
2.4 | Data entry and analysis
Data from the first stage were entered by an independent data entry 
specialist, and from the second stage by nurses and the lead author 
(F.V.S.). All entered data were subject to 2- pass verification.
We defined 2 populations for analysis: a safety set (SS, 
all patients at T1, first visit) and total analysis set (TAS, all 
patients with outcome at T2). Data on sociodemographic and 
disease- related variables are presented on the SS and data on 
treatment outcomes are presented on the TAS.
All analyses of the entered data are descriptive and were 
conducted using an Excel (Microsoft Corp.) and SPSS ver-
sion 25 (IBM).
3 |  RESULTS
3.1 | Patient population
From January to June 2016, 406 patients newly presenting at the 
NPH were screened, and 235 patients with an established diag-
nosis of epilepsy or reporting a first seizure in the preceding year 
were included. A total of 59 patients (25%) attended the NPH 
directly, whereas the remaining 176 patients (75%) were referred 
from other healthcare centers for specialist epilepsy care.
At 15- month follow- up, T2, nurses at NPH obtained in-
formation on 166 of 235 (70.6%) patients, including 5 deaths. 
Sixty- nine patients were lost to follow- up, predominantly be-
cause of disconnected telephone numbers.
3.2 | Sociodemographic data
More than 70% of the enrolled patients were aged <20 years. 
There was a 56% male preponderance (Table 1). Nearly 
two- thirds of patients lived outside the city of Kigali in rural 
areas. Most patients had private or social health insurance 
coverage, reducing their personal contribution for all medi-
cal care to 10% of the total cost. There were no important 
differences between SS and TAS in baseline demographics.
There was a low spontaneous reporting of HIV- positive 
serology, psychiatric comorbidity, and malnutrition: 1.7%, 
5.95%, and 1.28% respectively. Two- thirds of patients had an 
unknown HIV status.
The majority of patients aged ≥20 years, were single 
(67.4%), unemployed (41.5%), and had no formal education 
or a primary level education only (53.9%) (Table 2).
3.3 | Epilepsy characteristics and diagnosis
More than 80% of patients reported GTCS (generalized 
tonic- clonic seizures) and an additional 8% reported focal 
to generalized onset seizures. However, due to limited di-
agnostic resources, our seizure- type classification requires 
cautious interpretation. GTCS may include focal and gen-
eralized onset seizures and GTCS from unknown origin. 
More than half of patients reported 1- 5 seizures a month 
T A B L E  1  Sociodemographics of the patient populations (SS and 
TAS) and epilepsy disease characteristics at baseline T1
Demographics
SS TAS
n = 235 n = 166
Age (y)
Mean 15.6 14.77
Range 0- 78 0- 63
Age group, n (%)
0- 4 63 (26.8) 46 (27.7)
5- 9 36 (15.3) 29 (17.5)
10- 19 64 (27.2) 42 (25.3)
20- 39 55 (23.4) 39 (23.5)
≥40 16 (6.8) 10 (6.0)
Sex, n (%)
Male 132 (56.2) 93 (56)
Female 103 (43.8) 73 (44)
Health insurance status, n (%)
Social health care 164 (69.8) 120 (72.3)
Private insurance 42 (17.9) 28 (16.9)
Not insured 12 (5.1) 6 (3.6)
Unknown 17 (7.2) 12 (7.2)
Setting, n (%)
Rural 152 (64.7) 107 (64.5)
Urban (Kigali) 78 (33.2) 59 (35.5)
Abroad 5 (2.1) 0 (0)
Seizure type, n (%)
Generalized tonic- clonica 189 (80.4) 131 (78.9)
Focal aware motor/
non- motor
11 (4.7) 20 (12.0)
Focal impaired awareness 
motor/non- motor
2 (0.9) 3 (1.8)
Focal to bilateral 
tonic- clonic
19 (8.1) 1 (0.6)
Not classified 14 (6.0) 10 (6.0)
Alternative treatment use (reported >1%), n (%)
Never used for epilepsy 158 (67.2) 102 (61.4)
Prayers 10 (4.3) 38 (22.9)
Herbal medicine 16 (6.8) 12 (7.2)
Missing data 51 (21.7) 11 (6.6)
SS, safety set at study start T1; TAS, total analysis set at follow- up T2.
aDue to limited diagnostic resources, seizure type requires cautious interpretation; 
generalized tonic- clonic may include focal onset, generalized onset, and unknown 
origin. 
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(50.7%). Twenty patients (8.5%) reported >30 seizures a 
month (Table 1).
The mean age of patients at onset of seizures was 
10.8 years and 13.4 years at diagnosis, indicating a diagnos-
tic delay of >2.5 years. Yet, for patients aged ≥20 years, this 
delay increased to 4 years. Patient self- reported delay in diag-
nosis occurred in >33% (Table 2).
A total of 73% of patients underwent electroenceph-
alography (EEG) and with normal findings reported in 
59.8%. Other diagnostic techniques were rarely used; 
computed tomography (CT), magnetic resonance imag-
ing (MRI), and blood tests were conducted in 10, 7, and 
8 patients, respectively, with mostly normal results being 
reported.
Age groups 0- 4 5- 9 10- 19 20- 39 ≥40
N [unknown/missing] 63 36 64 55 16
Marital status, n (%)
Under age to get 
married
63 (100) 36 (100) 45 (70.3) NA NA
Single/co- living NA NA 18 (28.1) 41 (74.6) 3 (18.8)
Married NA NA 1 (1.6) 13 (23.6) 8 (50)
Widowed NA NA 0 (0) 0 (0) 2 (12.5)
Divorced NA NA 0 (0) 1 (1.8) 3 (18.8)
Education, n (%) [22]a
Had no education 0 (0) 0 (0) 4 (6.3) 5 (9.1) 3 (18.8)
Receives no 
education
60 (95.2) 14 (38.9) 5 (7.8) 0 (0) 0 (0)
Primary 3 (4.8) 21 (58.3) 28 (43.8) 22 (40) 4 (25)
Secondary 0 (0) 0 (0) 19 (29.7) 18 (32.7) 2 (12.5)
Higher 0 (0) 0 (0) 0 (0) 3 (5.5) 1 (6.3)
Employment, n (%) [10]a
Agricultural 
worker/farmer
NA NA 2 (3.1) 16 (29.1) 8 (50)
Commercial/state 
employee
NA NA 1 (1.6) 14 (25.5) 3 (18.8)
Unemployed/
pensioned
NA NA 13 (20.3) 4 (7.3) 2 (12.5)
Student 3 (4.8) 19 (52.8) 45 (70.3) 16 (29.1) 1 (6.3)
Age at epilepsy onset
59 [4] 33 [3] 62 [2] 53 [2] 13 [3]
Mean (y) 1.21 3.76 11.15 18.98 36
Range (min- max) 0- 4 0- 9 0- 19 0- 37 0- 78
Age at diagnosis
59 [4] 34 [2] 59 [5] 54 [1] 13 [3]
Mean (y) 1.73 5.3 13.54 23.92 40.23
Range (min- max) 0- 4 0- 9 0- 19 2- 38 2- 38
Monthly seizure frequency at baseline, n (%) [36]a
No seizures 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
1- 2 12 (18.8) 9 (25) 15 (23.4) 22 (40) 3 (18.8)
3- 5 13 (20.3) 8 (22.2) 21 (32.8) 10 (18.2) 5 (31.3)
6- 10 9 (14.1) 9 (25) 8 (12.5) 5 (9.1) 3 18.8)
11- 30 12 (18.8) 2 (5.6) 5 (7.8) 7 (12.7) 0 (0)
>30 9 (14.1) 3 (8.3) 4 (6.3) 4 (7.3) 0 (0)
NA, not applicable; SS, safety set, includes all patients at T1.
aIndicates number of patients with missing data on this demographic. 
T A B L E  2  Demographics and disease 
specifics by age group at T1, SS
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3.4 | Treatment profile at T1 and T2
At T1, 16 (6.8%) and 10 (4.2%) of patients in the SS indicated 
using traditional medicine or using prayers as epilepsy treatment. 
Because many patients were referred to NPH from other medi-
cal centers, 53 patients (31%) were already receiving treatment 
at baseline. The most frequently used treatment schedule was 
valproate monotherapy in all age groups, followed by carbamaz-
epine with a low percentage of patients using phenobarbital.
At T2, 5 of 166 patients (3%) had died and treatment data 
could not be validated in 4 patients. Of 157 remaining pa-
tients, 81 (52%) were taking AEDs, whereas 76 (48%) had 
stopped taking AEDs. Among those continuing AEDs, the 
majority were taking monotherapy (n = 63; 78%); 15 (18%) 
were taking duotherapy, and 3 (4%) triple therapy. The most 
frequently prescribed AED at T2 was valproate, part of the 
regimen in 79% of both monotherapy and combination treat-
ments. The second most frequently prescribed AED was car-
bamazepine in 22% (n = 19) of treatment schedules, followed 
by phenobarbital in 14.1% (n = 11) of patients.
Among the most frequently self- reported reasons for treat-
ment discontinuation were seizure cessation (31.7%), lack of 
money (30.4%), and insufficient information on treatment 
(20.7%). Given the large number of young patients in the 
study, reasons for treatment discontinuation were analyzed 
separately according to age (0- 19 vs ≥20 years). Notable 
differences were that lack of money and stating a lack of 
willpower led to more discontinuation among adults than 
children, whereas seizure cessation and insufficient informa-
tion were more frequently cited as reasons for discontinuation 
in the younger age group. Notably, only one patient reported 
treatment discontinuation due to AEs.
3.5 | Treatment outcomes
3.5.1 | Seizure frequency evolution from T1 
to T2
In the TAS population, seizure frequency per month, from 
baseline to follow- up, was available from 166 patients. A 
substantial reduction in seizure frequency relative to baseline 
(study start) was reported by all (Figure 1). Notably, 69.6% 
of patients reported that they had not experienced any sei-
zures in the previous month.
Because nearly half of patients had discontinued treat-
ment, seizure frequency was analyzed separately for pa-
tients who continued or had discontinued treatment with 
AEDs. Results were found to be similar in the 2 groups 
(Figure 2). Timing of discontinuation of treatment was not 
documented.
3.5.2 | Adverse events
Most patients (80.6%) reported no AEs (Table 3). The 
most frequently reported AEs were general weakness/fa-
tigue (8.1%), somnolence (5.0%), and weight gain (3.1%). 
Analyzed separately for patients who continued or discon-
tinued treatment, AEs occurred slightly less frequently in 
patients who discontinued compared to those who contin-
ued treatment (74.3% vs 86.5%). Conversely, those remain-
ing on treatment reported more frequently fatigue (12.8% 
vs 3.6%), somnolence (8.9% vs 1.2%), and hypersalivation 
(5.1% vs 0%).
At T2, 5 of 235 patients had died, resulting in a mortal-
ity rate of 2.12% in our cohort or a mortality rate of 21.27 
per thousand patient years. By use of the World Health 
Organization Verbal Autopsy Questionnaire,14 we identi-
fied the cause of death as brain tumor in 1 of 5 , blunt head 
trauma after a seizure in 1 of 5, and 3 of 5 of unknown 
origin. The latter may include possible sudden unexpected 
death in epilepsy (SUDEP) as no other concomitant disease 
was observed.
3.5.3 | Complications/comorbidities T2 
compared to T1
Patients/caregivers were asked for additional health 
problems/complications occurring during the follow- up 
period. Responses were obtained in 160 patients, with 
the majority not reporting any disease complications 
F I G U R E  1  Change in seizure 
frequency after 15 months (T2) of treatment 
compared to baseline T1
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or comorbidities (Table 4). Age- related differences in 
the type of complication were apparent: gait problems 
and growth/developmental delay were noted only in the 
youngest age group, whereas minor injuries and having 
to stop studies/job were frequently reported in the older 
age groups.
3.5.4 | Self- reported change in QoL at T2 
compared to T1
Using a 4- item scale, we measured the impression of change 
of QoL compared to baseline since the initial visit at the 
NPH. Of 159 responses obtained, most patients reported 
F I G U R E  2  Change in seizure frequency after 15 months of treatment among patients who had continued or discontinued therapy
AEs occurring in >2.5% of all patients
AEs, n (%)
Discontinued 
treatment (n = 82)
Continued 
treatment (n = 78)
All patients 
(n = 160)
No AEs 71 (86.5) 58 (74.3) 129 (80.6)
General weakness/fatigue 3 (3.6) 10 (12.8) 13 (8.1)
Somnolence 1 (1.2) 7 (8.9) 8 (5.0)
Weight gain 2 (2.4) 3 (3.8) 5 (3.1)
Hypersalivation — 4 (5.1) 4 (2.5)
Dizziness 3 (3.6) 1 (1.2) 4 (2.5)
Data are n (%).
T A B L E  3  Incidence of adverse events 
(AEs) reported at T1
Complications occurring in >2.5% of all patients
Complications, n (%) 0- 4 y (n = 76) 5- 19 y (n = 41) ≥20 y (n = 43)
No complications mentioned 60 (78.9) 31 (75.6) 26 (60.4)
Minor injuries 2 (2.6) 5 (12.1) 7 (16.2)
Stopped studies/job 1 (1.3) 2 (4.8) 8 (18.6)
Behavioral problems 2 (2.6) 1 (2.4) 2 (4.6)
Burns 2 (2.6) — 2 (4.6)
Growth/developmental delay 4 (5.2) — —
Gait problems 1 (1.3) — —
Study- related issues 2 (2.6) 1 (2.4) —
Road accident — 1 (2.4) —
Social isolation — 1 (2.4) —
Fall with fracture — — 2 (4.6)
T A B L E  4  Incidence of comorbidities 
reported at T2
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an improvement in their day- to- day life. Marked, partial 
improvement, no improvement, and deterioration were re-
ported by 50.9%, 32.7%, 7.5%, and 8.8%, respectively. Of 
76 patients who discontinued AEDs, 42 seizure- free patients 
without AEs at T2 reported a marked or partial improvement 
of QoL. On the other hand, of 22 patients who discontinued 
AEDs and reported AEs and comorbidities, none reported a 
marked improvement.
4 |  DISCUSSION
To our knowledge, this is the largest study to date in Rwanda in 
an epilepsy cohort, reporting demographics, seizure manage-
ment, and outcomes in a national referral center for epilepsy. 
Because research in 2005 demonstrated a high prevalence of 
epilepsy in Rwanda, up to 49 in 1000, 10- fold the rate in de-
veloped countries, there is a need for understanding the needs 
of patients and gaps in patient care in Rwanda.7
Our cohort of 235 patients had a broad age distribu-
tion, ranging from 1- to 78- years- old, with a substantial 
proportion younger than 20 years: up to 42% of the chil-
dren included in our study were younger than10 years 
old and 24% were even younger than 2 years. This very 
young age representation, although not uncommon in ep-
ilepsy, needs further attention. Indeed, limited informa-
tion is available on the etiology and exact diagnosis of 
seizure type or syndrome. In future studies, we need to 
address the etiology of epilepsy using imaging and lab 
tests as well as a detailed review of the perinatal records. 
This recommendation applies also to our broader study 
population. Indeed, the number of patients with known 
HIV status, number of further investigations using a 
broad infectious disease screening or imaging is low. To 
improve quality of care we recommend expanding the 
use of EEG by trained personnel. Also, increasing the 
use of imaging techniques, such as MRI, and increasing 
the availability of lab tests should improve the quality 
of care. Recommendations and views for future labora-
tory deployments have been provided by Nkengasong 
et al.15 However, in a resource- constrained environment, 
expanding these activities may be challenging and will 
require substantial healthcare investment. For example, 
the price of a magnetic resonance imaging (MRI) study 
in Rwanda is 150 USD or 15 USD for insured patients, 
whereas the average monthly salary in Rwanda is about 
160 USD.16
It is encouraging that the majority of PwE had health 
insurance coverage, enabling them to cover their treatment 
costs. Still, 26%- 41% of those who stopped their treatment 
reported that they could not cover the costs of the treatment, 
including non- medical costs, such as transportation. Possible 
contributing factors to this lack of financial power include a 
lower schooling degree, unemployment, or ongoing school-
ing. Indeed, only 61% of patients above 20 years of age, re-
ported an economic activity and 48% had no education or had 
attended only primary school. It is unclear whether this is due 
to stigma or cognitive decline in our patients.17–19
Several findings point to stigmatization of PwE. Sebera 
et al20 reported in 2005 that more than two- thirds of the 
Rwandan population considered PwE not apt to get married. 
In our study, only 1 in 4 PwE was married. Low schooling 
and employment rate are indirect measures of stigma, as PwE 
may not get similar chances as nonaffected patients. To en-
large the support from the general population for PwE, ad-
ditional awareness campaigns are needed, in particular for 
traditional healers and community workers.
Another reassuring finding was the seizure evolution in 
our study. Up to 62% of 166 PwE from the T2 group, or 46,8% 
of the T1 group, were seizure free at T2. Most patients were 
taking valproate monotherapy. A high percentage of patients 
who stopped treatment reported 30- day seizure freedom at 
T2. Although 30- day seizure freedom does not qualify for 
inactive epilepsy, this number has been reported elsewhere. 
In a study in children with epilepsy in Kenya, a high number 
of inactive epilepsy was also found in 80% of nontreated pa-
tients.21 A possible reason may be regional factors with low 
risk of recurrence, which needs to be elucidated by better 
etiologic research. On the other hand, from a cultural per-
spective, short- term seizure freedom is often considered a 
motive to stop treatment by patients; this reinforces the need 
for better patient education regarding compliance with treat-
ment.  Although we need to be cautious at interpreting these 
high seizure-freedom rates, those numbers might represent a 
legitimate good outcome, considering the resource constraint 
environment and the need for a pragmatical approach in clin-
cal assessments and treatments.
The AED treatment prescribed in a majority of patients 
was valproate. This is surprising, as the first- line AED of 
choice in Rwanda is phenobarbital. However, from a prag-
matic standpoint, with valproate having a broad spectrum and 
good availability in the center, it is a good choice in cases 
of difficult seizure classification and lacking adequate etio-
logic assessment. The low rate of use of traditional healing 
practices is surprising and in contrast to the findings in 2005, 
possibly explained by underreporting or by the fact that the 
clinic is a referral center.7
The self- reported marked improvement of QoL parallels 
the seizure- frequency evolution. In addition, of those who 
discontinued their AEDs and remained seizure- free, the im-
provement remained stable.
Our reported outcome data may be biased because only 
the PwE who could be contacted were included (TAS). Given 
that the patients who were lost to follow- up might experience 
worse seizure control, this study may overestimate seizure 
control and outcome.
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We reported 5 deaths in this study, which suggests a high 
mortality rate of 21.2 per 1000 patient years. In a post- hoc 
follow- up, we identified 3 unknown causes of death, using 
World Health Organization (WHO) verbal autopsy methodol-
ogy. Although this methodology is straightforward, it proved 
to be labor- and cost- intensive. We advocate further use of 
the verbal autopsy methodology for all deaths due to epilepsy 
as the best available technique to evaluate mortality in PwE 
when autopsy is not available.1,11 Population- based studies 
have shown that long- term mortality rate in PwE is up to dou-
ble the mortality rate of the general population.22 Because 
the young age of our population, the rather short period of 
follow- up, and the type and severity of the seizures may be 
confounding factors, further studies on mortality rates of epi-
lepsy in sub- Saharan populations are clearly needed.23–25
A high number of patients was lost to follow- up. The main 
reason for this loss was our inability to reach enrolled pa-
tients due to disconnected phone numbers. The high drop- out 
rate may be an indicator that PwE lack the incentive of any 
kind to seek follow- up. Considering that epilepsy is a disease 
with high burden, this gap highlights the need for an adjusted 
approach to PwE in Rwanda.4,6,26 In a poststudy interven-
tion, a trained nurse made field trips to visit patients in their 
own homes, which resulted in retrieving 62 of 69 patients 
previously lost to follow- up; these results will be published 
separately.
Not only follow- up was difficult in our cohort, also treat-
ment compliance needs attention in PwE. Up to 46.1% of the 
166 PwE at T2 had stopped their medication without the con-
sent of their treating clinicians. Many patients mentioned lack 
of sufficient information on epilepsy and treatment and lack 
of financial means, due to high non- medical costs (transpor-
tation). We conclude that enhanced patient and family educa-
tion is needed as well as ensuring attention to the economic 
status of patients. Adequate ways of communicating medical 
information will need to be created and a one- fits- all format 
will probably not apply.27
The pragmatic approach of clinicians in Rwanda that is 
focused on seizure reduction is also reflected in the limited 
availability of clinical data on seizure type and syndromic 
classification in our population. Indeed, up to 80% of sei-
zures were classified as generalized tonic- clonic seizure 
(GTCS), which is unexpectedly high when compared to 
other series in developed countries, in which 51%- 64% of 
seizures are reported to be focal.28 The probability of seizure 
type misclassification is likely. To improve adequate classi-
fication that may lead to better treatment, increased capac-
ity building and improving availability to diagnostic testing 
specific to neurology and epilepsy is needed. Training of a 
larger number of neurologists is of paramount importance 
but will take time. In 2005, 3 neurologists were available 
in Rwanda to serve a population of 11 million inhabitants. 
Currently, Rwanda counts 4 active neurologists, or less than 
1 per 2 million inhabitants. In addition, suggested interven-
tions include keeping standardized medical records, creating 
and implementing local AED treatment guidelines, using 
validated QoL scales and registries, and setting up a more 
streamlined referral system.
Our ambispective cohort study has other limitations. First, 
the retrospective analysis of medical records proved to be 
difficult as medical notes were not standardized. This con-
tributed to a high volume of missing data, poor seizure clas-
sification skewing toward GTCS not otherwise specified, and 
undocumented etiologic or syndromal assessments. Second, 
we already pointed toward the lack of validated scales and 
limited follow- up possibilities. Efforts for standardization 
and capacity building are ongoing. Third, potential reporting 
bias is possible due to the choice of telephone consultation 
and the issues in translation between author and nurse, and 
toward patients.
In conclusion, encouraging results on seizure con-
trol and improved QoL have been achieved in Rwanda. 
However, a high number lost to follow- up suggests that 
epilepsy remains difficult to tackle. Our most important 
finding is that the epilepsy treatment gap is still import-
ant, based on patient- centered, medical, institutional, and 
healthcare- related factors. The key to improvements lies in 
all factors, with a better understanding of the patients’ cul-
tural concepts of epilepsy and its treatment, optimal drug 
supply and availability, and improved education among gen-
eral practitioners and other primary care medical person-
nel, supported by solid research data from the community. 
Further studies using improved questionnaires need to be 
conducted on the prevalence of epilepsy and its risk factors, 
economic analysis of epilepsy treatment, QoL, SUDEP, and 
other epilepsy- associated (co- ) morbidity and mortality. 
Some interventions, such as improved and standardized pa-
tient record keeping, may be achievable in the short term. 
Concerted efforts of different stakeholders at all levels of 
the healthcare system will be needed and may take time be-
fore a transformational change can be achieved.29
Therefore, this paper is an invitation to all readers to en-
gage with the authors in Rwanda, sharing their expertise at the 
patient level, hospital level, and/or healthcare level. Needless 
to say, the energy and passion of the locals and local profes-
sionals involved in the field is heroic and should be praised.
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